• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Seattle Genetics

Seattle Genetics

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

    Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

  2. Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma

    Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma

  3. UPDATE: Bull trend intact: S&P 500 rallies from the breakout point

    UPDATE: Bull trend intact: S&P 500 rallies from the breakout point

  4. UPDATE: Bull trend intact: S&P 500 rallies -2-

    UPDATE: Bull trend intact: S&P 500 rallies -2-

  5. Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting

    Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting

  6. UPDATE: Bull trend intact: Charting the S&P 500's garden-variety pullback

    UPDATE: Bull trend intact: Charting the S&P 500's garden-variety pullback

  7. UPDATE: Bull trend intact: Charting the S&P -2-

    UPDATE: Bull trend intact: Charting the S&P -2-

  8. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  9. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

  10. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.